CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J.
Berger, M.D., chairman and chief executive officer, will provide an
overview of the Company’s business at two upcoming investor conferences:
-
The 14th Annual BIO CEO & Investor Conference in New York
City. Dr. Berger’s presentation is on Monday, February 13 at 9:00 a.m.
(ET)
-
The Leerink Swann 2012 Global Healthcare Conference in New York
City. Dr. Berger’s presentation is on Wednesday February 15 at 3:30
p.m. (ET)
Both presentations will be webcast live and can be accessed by visiting
the investor relations section of the Company's website at http://www.ariad.com/investor.
A replay of the presentation will also be available and archived on the
site for three weeks.
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company
focused on the discovery, development and commercialization of medicines
to transform the lives of cancer patients. ARIAD’s approach to
structure-based drug design has led to three internally discovered,
molecularly targeted product candidates for drug-resistant and
difficult-to-treat cancers, including certain forms of chronic myeloid
leukemia, soft tissue and bone sarcomas and non-small cell lung cancer.
For additional information, visit http://www.ariad.com.
Source: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
For Investors
Maria E.
Cantor, 617-621-2208
Maria.cantor@ariad.com
or
For
Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
